<DOC>
	<DOCNO>NCT00453635</DOCNO>
	<brief_summary>This trial compare efficacy sequential administration Docetaxel , Carboplatin Herceptin versus administration Vinorelbine Herceptin combination first line treatment HER-2 positive patient metastatic breast cancer .</brief_summary>
	<brief_title>Study With Docetaxel , Carboplatin Herceptin Versus Vinorelbine Herceptin HER-2 ( + ) Metastatic Breast Cancer Patients</brief_title>
	<detailed_description>Herceptin , humanize monoclonal antibody direct extracellular domain transmembrane glycoprotein HER2/neu ( c-erbB-2 ) , valuable option treatment woman HER2-positive metastatic breast cancer . The combination Herceptin chemotherapy yield significantly good result chemotherapy alone response , time progression , survival time . Whether combination Docetaxel , Carboplatin Herceptin versus administration Vinorelbine Herceptin combination HER-2 positive patient metastatic breast cancer preferable yet know .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Performance status ( WHO ) 02 Histologically confirm metastatic breast adenocarcinoma ( stage IV ) without prior chemotherapy receive HER2 overexpression 2+ 3+ use IHC FISH + Measurable disease prior irradiation field ( concurrent chemotherapy agent ) No 25 % myeloproductive bone marrow irradiate ( 4 week since prior radiotherapy recover ) More 6 month since prior adjuvant neoadjuvant chemotherapy recover No prior first line chemotherapy metastatic disease Endocrine therapy allow adjuvant first line treatment metastatic disease Paraffin block primary tumor available research lab Adequate bone marrow function ( absolute neutrophil count &gt; 1000/mm^3 , platelet count &gt; 100000/mm^3 , hemoglobin &gt; 9 gr/mm^3 ) Adequate liver ( Bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2mg/dl ) Adequate cardiac function ( LVEF &gt; 50 % ) Informed consent Pregnant nursing Concurrent agent ketoconazole , macrolide antibiotic , zidovudine may induce P450 cytochrome Positive pregnancy test Motor sensory neuropathy &gt; grade 1 accord NCIC Î¤oxicity Criteria Patients brain metastatic disease irradiate uncontrolled brain metastatic disease irradiation History allergic reaction attribute docetaxel Psychiatric illness social situation would preclude study compliance Other concurrent uncontrolled illness . Other invasive malignancy within past 5 year except cure basal cell skin carcinoma cervical carcinoma situ</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>First line treatment</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Vinorelbine</keyword>
</DOC>